Volpara Health Technologies (ASX:VHT) has provided a business update, including a new contract with Sutter Health for its Risk Pathways product.
The breast cancer detection company says the contract will represent an additional $1.4M in Total Contract Value over an initial three-year period and expands existing Contracted Annual Recurring Revenue to $595k.
It also says presentations and posters presented at the European Congress of Radiology (ECR) validate its software, and that it's also participating in an AI in Healthcare panel discussion with Microsoft and Alcidion in Sydney.
Shares of Volpara Health Technologies were up more than 3% this afternoon.